Abstract:The survival benefit of checkpoint immunotherapies is currently limited, with de novo and acquired resistance to therapy occurring in over 75% of patients. A major mechanism of resistance accounting for these poor responses is a lack of tumor immunogenicity, resulting from loss of function mutations in antigen presentation pathways (e.g., B2M, MHC1), or a lack of tumor expressed neoantigens. Dual-antibody T cell engagers (DATE) represent a promising immunotherapeutic approach for poorly immunogenic tumors as these agents engage CD3 on T cells while binding a tumor-associated antigen, resulting in intratumoral T-cell activation, independent of antigen recognition or co-stimulation. To harness the therapeutic potential of this approach for treatment of clear cell renal cell carcinoma (ccRCC), a carbonic anhydrase 9 (CA9) targeting DATE was developed, given the near ubiquitous and selective expression of this antigen on ccRCC tumors. To engineer the CA9-DATE, a panel of CA9 antigen binding fragments (Fabs) was developed through phage display and characterized for CA9-membrane fragment esterase inhibition. A CA9-inhibiting Fab was subsequently cloned into a mammalian expression system containing the anti-CD3 single chain variable fragment. CA9-DATE binding specificity was measured by flow cytometry utilizing a panel of CA9-expressing and -knockout cell lines. Functionally, T-cell activation was assessed through CD25 levels using flow cytometry and IFN-γ secretion using ELISA. In vitro T-cell mediated cytotoxicity was tested utilizing luciferase expressing ccRCC cells and LDH release assays. Finally, humanized NOG mice bearing patient-derived RCC tumors were employed for in vivo efficacy studies. CA9-DATE showed antigen-specific binding towards both CD3- and CA9 in the low-nanomolar ranges. CA9-DATE treatment of patient-derived ccRCC cell lines co-cultured with healthy isolated CD3+ lymphocytes or peripheral blood mononuclear cells resulted in rapid CD4+ and CD8+ lymphocyte activation characterized by a proliferative response, increased CD25 expression, and IFN-γ production. In addition, CA9-DATE resulted in CA9 specific-lysis across 5 patient-derived ccRCC cell lines in in vitro cytotoxicity assays. Preliminary in vivo results demonstrate significant reductions in tumor burden following CA9-DATE therapy relative to vehicle control-treated mice. Collectively, these data provide proof of principle to support the clinical study of CA9-DATE targeting strategies in clear cell RCC. Citation Format: Jason Moffat, Xiaoyu Zhang, Keith Lawson, Sunandan Banerjee, Xiaowei Wang, Jarrett Adams, James Pan, Laurie Ailles, Antonio Finelli, Sachdev Sidhu. Development and characterization of a novel CA9 targeting dual-antibody T-cell engager for renal cell carcinoma [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr B49.

T cell receptor-engineered T cells targeting a human endogenous retrovirus in kidney cancer.

Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus

Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).

Inactivation of the von Hippel-Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

Quantification of circulating TCR-engineered T cells targeting a human endogenous retrovirus post-adoptive transfer using nanoplate digital PCR

Abstract B49: Development and characterization of a novel CA9 targeting dual-antibody T-cell engager for renal cell carcinoma

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers

Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy

A T cell receptor specific for an HLA-A*03:01-restricted epitope in the endogenous retrovirus ERV-K-Env exhibits limited recognition of its cognate epitope

Abstract LB340: Harnessing the gp70 endogenous retrovirus envelope protein as a universal tumor antigen for T cell therapy in mice

Abstract 26: An HLA-class II restricted HPV18 E7 specific TCR cloned from a long-term surviving cervical cancer patient

HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice

Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor Beta-Insensitive CD8(+) T Cells

Identifying and engineering TCR specificity against solid tumor neoantigens

Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma

Endogenous retrovirus expression and its impact on tumor-infiltrating immune cells in papillary renal cell carcinoma.

Abstract 4092: Characterizing the endogenous retroviral envelope protein ERVMER34-1 as a target for a therapeutic cancer vaccine

Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma

Peptide-MHC-targeted retroviruses enable in vivo expansion and gene delivery to tumor-specific T cells

Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses